Pirfenidone ameliorates the formation of choroidal …

Loading...

Taking too long?

Reload document

| Open in new tab

2162

Molecular Medicine rePorTS 21: 2162-2170, 2020

Pirfenidone ameliorates the formation of
choroidal neovascularization in mice

YUEQI BAO1*, LILI HUANG1*, XIAOBO HUANG1, CHUANG GAO1, YU CHEN1,
LIUCHENG WU2, SHUNXING ZHU2 and Yu SonG1

1Department of Ophthalmology, Affiliated Hospital 2 of Nantong University;
2Laboratory Animal Center of Nantong University, Nantong, Jiangsu 226001, P.R. China

Received July 19, 2019; Accepted November 18, 2019

DOI: 10.3892/mmr.2020.11007

Abstract. The formation and development of choroidal
neovascularization (cnV) is accompanied by inflamma-
tion and fibrosis. Existing treatments are expensive and can
cause irreversible complications. Pirfenidone (PFD) exerts
anti‑inflammatory and anti‑fibrotic effects; however, its appli-
cations in the eye remain unclear. Male C57BL/6J mice (aged
6‑8 weeks) were used to explore whether PFD can inhibit the
formation of laser‑induced CNV. The localization of trans-
forming growth factor β2 (TGFβ2) was determined through
immunofluorescent staining. After laser photocoagulation,
the vehicle and PFD groups were intravitreally injected with
1 µl PBS and 1 µl 0.5% PFD, respectively. At day 7 after
intravitreal injection, the expression of TGFβ2 and vascular
endothelial growth factor (VEGF) was assessed. Fundus fluo-
rescein angiography was performed to investigate the extent of
fluorescence leakage, and the CNV areas were analyzed using
a choroidal flat mount. The results demonstrated that, on day 7
after photocoagulation, the expression of TGFβ2 and VEGF
was reduced in the experimental group. In addition, fluorescein
angiography showed that the leakage area of CNV was signifi-
cantly smaller in the PFD injection group than those observed
in the control and vehicle groups. Moreover, the areas of CNV
in the PFD injection group were smaller compared with those
reported in the other two injection groups. Histopathological
and Tunel analyses performed on day 28 revealed that there
were no notable abnormalities on the layers of the neural retina
of PFD‑treated mice. In conclusion, intravitreal injection of
PFD inhibited the formation of CNV in mice, likely via the

Correspondence to: Dr Yu Song, Department of Ophthalmology,
Affiliated Hospital 2 of Nantong University, 6 Haier Lane North
Road, Nantong, Jiangsu 226001, P.R. China
E‑mail: songyuleye@126.com

*contributed equally

Key words: choroidal neovascularization, pirfenidone, transforming
growth factor β2, vascular endothelial growth factor

downregulation of VEGF and TGFβ2, which did not cause
damage to the mouse retina after 28 days of treatment.

Introduction

Age‑related macular degeneration (AMD) is the leading cause
of vision loss among individuals aged >50 years in industri-
alized nations (1). Wet AMD is characterized by choroidal
neovascularization (CNV), wherein new blood vessels disrupt
Bruch’s membrane and grow towards the outer retina from
the underlying choroid (2). These immature blood vessels
are more prone to leaking and bleeding, thus causing severe
impairment of visual acuity (3). CNV is a process involving
both inflammation and angiogenesis (3,4). Vascular endothelial
growth factor (VEGF) inhibitors (ranibizumab, bevacizumab
and aflibercept) are the current standard of care for AMD (5).
Although anti‑VEGF treatment generally stabilizes and
improves visual acuity, not all patients benefit from this type
of therapy (5). There is evidence suggesting that the inhibi-
tion of transforming growth factor β (TGFβ) may be a novel
therapeutic approach in the treatment of CNV (6,7).

TGFβ is part of a superfamily of peptide growth factors,
regulating a wide range of cellular functions during develop-
ment and maintaining adult tissue homeostasis (8). High
expression of TGFβ is associated with the expression of angio-
genic factors and increased new vessel formation (9). Three
separate TGFβ isoforms (TGFβ1, TGFβ2 and TGFβ3) have
been identified in mammals, and share 70‑82% homology at
the amino acid level (10). Among them, TGFβ2 is predominant
in normal aqueous and vitreous humor (11,12). VEGF is found
in numerous ocular tissues of both healthy and diseased eyes,
and it plays a critical role in the development of CNV (13). In
AMD, there is evidence that TGFβ2 induces the upregulation
of VEGF mRNA expression and protein secretion of VEGF
by the retinal pigment epithelium (RPE) and choroid cells (14).
Pirfenidone [5‑methyl‑1‑phenyl‑2‑(1H)‑pyridone; PFD] is a
non‑peptide, low‑molecular weight compound. It was initially
evaluated as an anti‑inflammatory agent, and subsequently
developed as an anti‑fibrotic drug (15). Its anti‑inflammatory
effect is attributed to tumor necrosis factor-α (TNFα) (16).
notably, it reduces the proliferation and differentiation of
fibroblasts into myofibroblasts by inhibiting key factors in the
TGFβ pathway (17). The safety and efficacy of PFD have been

BAO et al: PIRFENIDONE AMELIORATES CHOROIDAL NEOVASCULARIZATION

2163

clinically evaluated in numerous disorders. In multinational
phase 3 trials involving patients with idiopathic pulmonary
fibrosis, the administration of PFD significantly reduced
disease progression with an acceptable safety profile (18,19).
in a randomized, placebo-controlled trial that included 77
patients with diabetic kidney disease, treatment with PFD
led to an improvement in the estimated glomerular filtration
rate and was not associated with severe adverse effects (20).
PFD is applied to the eye in the following clinical situations:
Ocular surface diseases; glaucoma filtration surgery; posterior
capsular opacification; and post‑traumatic proliferative vitreo-
retinopathy (21).

Nevertheless, the relationship between PFD and CNV
has not been investigated. Based on the peak time of CNV
development (22,23), day 7 (after laser photocoagulation) was
selected to demonstrate the influence of PFD on the formation
of CNV and its effect on VEGF.

Materials and methods

Animals. A total of 63 male C57BL/6J mice (age: 6‑8 weeks;
weight: 20‑25 g) were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd. The animals were housed in
specific cages with ad libitum access to food and water in a
room with a 12/12‑h light/dark cycle. The humidity and temper-
ature were maintained at 50±5% and 23±1˚C, respectively.
All experimental procedures were performed in accordance
with the requirements of the Animal Welfare Committee of
Nantong University [permit nos. SCXK(Su)2014‑0001 and
SYXK(Su)2017‑0046]. This study adhered to the Association
for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research (24). The
research protocol for the use of animals was approved by the
Center for Laboratory Animals of Nantong University.

Intravitreal injection. In this experiment, 54 mice were
randomly divided into three groups (n=18/group): Control,
vehicle and PFD. The control group and the remaining 9 mice
(normal group) received no treatment. The injury induced by
CNV and the potential toxicity of PFD in the control, vehicle
and PFD groups were compared to the normal group (4 mice
were used in choroidal flat mount experiment and 5 mice
were used in the histopathological examination, respectively).
As described in a previous experiment (25), an intravitreal
injection of 1 µl 0.5% PFD (Beijing Kangdini Pharmaceutical
Co., Ltd.), or vehicle (0.01 M PBS solution: Sodium chloride,
137 mM; disodium phosphate dodecahydrate, 9 mM; and
sodium dihydrogen phosphate dehydrate, 2.9 mM) was admin-
istered on day 0 to the PFD and vehicle group, respectively.
Mice were decapitated at day 7 and 28 following anesthesia
(5% isoflurane).

Laser‑induced CNV. The induction of CNV was carried out
immediately after drug application. Anesthesia was induced in
54 mice (control, vehicle and PFD group) through inhalation
of isoflurane (induction: 5%, maintenance: 1%), and the pupils
were dilated with topical administration of tropicamide phen-
ylephrine eye drops (Santen Pharmaceutical Co., Ltd.). Mice in
the normal group (n=9) were not induced. Following mydriasis,
the mice were placed on a platform under the slit lamp and a

laser‑induced CNV model was established due to rupture of
the Brunch’s membrane, as previously described (26). Laser
photocoagulation (532‑nm laser, 200‑mW, 100‑ms duration,
50‑µm spot size) was performed bilaterally in each mouse.
Laser spots were performed in a standard manner around the
optic nerve using a slit lamp delivery system (Vision One;
Lumenis), with a handheld cover slip used as contact lens.
Photocoagulation lesions were performed in a peripapillary
distribution at a distance of 1-2 disc diameters from the optic
nerve, avoiding major vessels. The appearance of a bubble
following laser treatment, which indicates a rupture of the
Bruch’s membrane, is an important factor in the induction of
CNV. Therefore, only burns in which a bubble was produced
were included in subsequent experiments. Spots with hemor-
rhage or absence of a bubble at the laser site were excluded
from the analysis. The eye was subsequently coated with
an antibiotic eye ointment. Afterwards, the CNV grade was
evaluated, as previously described (25). The control group
represented laser‑induced CNV without an injection of PFD
or vehicle

Immunofluorescence. Eyes were enucleated, fixed in 4%
paraformaldehyde for 24 h at 4˚C, and sectioned into cryosec-
tions (5 µm) at ‑20˚C to determine the localization of TGFβ2
using a specific antibody (27,28). The cryosections were
blocked with 5% BSA (Sigma‑Aldrich; Merck KGaA) for 2 h
at room temperature and incubated with mouse monoclonal
anti‑TGFβ2 antibody (1:50; cat. no. ab36495; Abcam) at 4˚C
overnight. The slides were incubated with the secondary anti-
body, Alexa Fluor® 488 donkey anti‑mouse IgG H+L (1:200;
cat. no. A‑21202; Thermo Fisher Scientific, Inc.) for 2 h, and
then DAPI for 5 min, both at room temperature. The sections
were imaged using a fluorescence microscope (magnification,
x200; Olympus Corporation).

Western blotting. The RPE‑choroid‑sclera complex was
extracted from 5 mice in each group on day 7 after intravitreal
injection to detect the protein levels of molecules. The tissues
were homogenized and solubilized in RIPA lysis buffer (cat.
no. R0278; Sigma‑Aldrich; Merck KGaA), containing 1%
protease inhibitors and 1% phosphatase inhibitors (Thermo
Fisher Scientific, Inc.). Protein concentration in the superna-
tant was quantified using a spectrophotometer (NanoDrop™
1000; NanoDrop Technologies; Thermo Fisher Scientific,
Inc.). The proteins (25 µg), according to their concentration
and a molecular weight marker, were loaded on a 10% SDS
gel and subjected to SDS‑PAGE. Proteins were subsequently
transferred to a polyvinylidene difluoride membrane and
blocked with 5% skim milk for 2 h at room temperature. The
membrane was incubated with mouse monoclonal anti‑TGFβ2
antibody (1:1,000; cat. no. ab36495; Abcam), VEGF rabbit
polyclonal antibody (1:5,000; cat. no. 19003‑1‑AP; ProteinTech
Group, Inc.) and mouse monoclonal antibody against GAPDH
(1:2,000; cat. no. AT0002; CMCTAG; Engibody Biotechnology,
Inc.) at 4˚C overnight. Then, the membranes were incubated
with horseradish peroxidase‑conjugated secondary antibodies
(1:2,000; cat nos. SA00001‑1 and SA00001‑2; ProteinTech
Group, Inc.) at 37˚C for 2 h, and washed in Tris‑buffered saline
and Tween‑20 (20 mM Tris‑chloride, pH 7.5; 137 mM sodium
chloride; and 0.1% Tween‑20). The blots were then incubated

2164

Molecular Medicine rePorTS 21: 2162-2170, 2020

Figure 1. Changes in the mouse retina 1 week after laser photocoagulation. (A) FFA revealed the presence of hyperfluorescence leakage in the laser‑induced
spots (white arrows) compared with control (magnification, x100). (B) H&E staining of the mouse retina showed that the fibrovascular complex broke the RPE
into the subretinal space after laser photocoagulation compared with control. Scale bar, 50 µm. RPE, retinal pigment epithelium; OS, outer segment; IS, inner
segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; CNV, choroidal
neovascularization; FFA, fundus fluorescein angiography.

with WesternBright ECL (APG Bio, Ltd.) and exposed to an
image analysis system (Tanon 5200 Multi; Tanon Science and
Technology Co., Ltd.). The intensity of GAPDH was used as
the control, and the optical density of bands was quantified
using Image J version 1.47 software (National Institutes of
Health).

Fundus fluorescein angiography (FFA). At 1 week after
laser photocoagulation or intravitreal injection, fundus
examinations were performed on 18 mice under general
anesthesia. Thereafter, the mice were euthanized as previously
described. Mice had their pupils dilated, and a digital fundus
camera was used to image the back of the eye (Heidelberg
Retina Angiograph II; Heidelberg Engineering, Inc.). The
laser‑induced lesions were studied using FFA to evaluate the
development of CNV. FFA images were captured 2‑5 min
after intraperitoneal injection of 0.3 ml 2% fluorescein sodium
(Guangxi Yinzhou People’s Pharmaceutical Co., Ltd.) (29).
Angiograms were graded as follows: Not stained, score 0;

slightly stained, score 1; moderately stained, score 2; strongly
stained, score 3 (30,31).

Choroidal flat mount. At 1 week after the CNV‑inducing laser
procedure or intravitreal treatment, 15 mice (10 eyes/group)
were euthanized; the eyes were enucleated and fixed in 4%
paraformaldehyde solution for 1 h at room temperature. The
RPE‑choroid‑sclera complexes were obtained by removing
the anterior segments and the neural retina, using an opera-
tion microscope (Olympus Corporation). Subsequently, the
complexes were washed in PBS containing 0.5% bovine serum
albumin, 0.2% Tween‑20 and 0.1% Triton‑X 100. Eyecups
were incubated with fluorescein Griffonia simplicifolia lectin i
isolectin B4 (1:100; cat. no. FL‑1201; Vector Laboratories Inc.)
overnight at 4˚C to label invading choroid vessels and washed
three times in PBS. After staining, the eyecups were flattened
through four to six radial cuts from the edge to the equator, and
flat mounted with the scleral side facing down onto a micro-
scope slide. The flat mounts were analyzed using a fluorescence

BAO et al: PIRFENIDONE AMELIORATES CHOROIDAL NEOVASCULARIZATION

2165

Figure 2. Immunolocalization of TGFβ2 in the mouse retina. Cryosections of the mouse retina were marked with TGFβ2 (green) and cell nuclei were labeled
with DAPI (blue). Localization and expression of TGFβ2 (white arrow heads) in the mouse retina differed between different days. Scale bar, 50 µm. OS, outer
segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell
layer; TGFβ2, transforming growth factor β2.

microscope (magnification, x100; Olympus Corporation). The
size of isolectin B4‑positive CNV areas was quantified with
Image J software (National Institutes of Health).

Histopathological examination. After the animals were
sacrificed, the eyeballs were enucleated, fixed in 4% para-
formaldehyde solution overnight at 4˚C, conventionally
dehydrated and embedded in optimal cutting temperature
compound to produce cryosections at ‑20˚C. The optic nerve
parallel to the sagittal plane at the laser photocoagulation
position was selected, and slices (thickness, 5.0 µm) were
continuously prepared. The sections were stained with hema-
toxylin‑eosin (H&E) for 3 min at room temperature, observed,
and photographed using a light microscope (magnification,
x200; Olympus Corporation).

Thermo Fisher Scientific, Inc.). Positive and negative controls
were included by adding deoxyribonuclease I reaction mixture
and omitting the TdT enzyme reaction mixture, respectively.
TUNEL‑positive cells were observed in >4 randomly selected
fields under a fluorescent microscope (magnification, x200).

Statistical analysis. All values are presented as the mean ± SD.
One‑way ANOVA was used for statistical comparisons
between multiple groups. All pairwise multiple comparisons
were performed using the Bonferroni test. Descriptive statis-
tics were performed using the SPSS version 22.0 software
(IBM Corp.). P<0.05 was used to indicate statistical signifi- cance. Each experiment was performed in triplicate. Results TUNEL. Cryosections (‑20˚C; 5 µm) were permeabilized with 10% proteinase K, after fixing in 4% paraformalde- hyde solution at room temperature for ~30 min according to the manufacturer's protocol (One Step TUNEL Apoptosis Assay Kit; Nanjing KeyGen Biotech Co., Ltd.). Apoptotic cells were treated with terminal deoxynucleotidyl transferase (TdT) enzyme reaction mixture (1 µl TdT enzyme and 4 µl biotin‑11‑2'‑deoxyuridine 5'‑triphosphate diluted in 1 ml equilibration buffer) at 37˚C for 45 min and detected using streptavidin‑fluorescein. Subsequently, the slides were washed with PBS three times (15 min each) and sealed with mounting medium (cat. no. 4112APG; Richard‑Allan Scientific™; Formation of CNV in the mouse retina after laser injury. at 1 week after laser photocoagulation, FFA was performed in normal (without CNV or treatment) and CNV model mice to examine the formation of CNV (Fig. 1A). The laser‑induced spots showed hyperfluorescent leakage, indicating rupture of Bruch's membrane and the formation of CNV. Histological analysis of the retina stained with H&E (Fig. 1B) also confirmed the formation of CNV on day 7 after laser‑induced rupture of Bruch's membrane. Localization of TGFβ2 changes in the mouse retina after laser injury. As shown in Fig. 2, TGFβ2 is expressed in both 2166 Molecular Medicine rePorTS 21: 2162-2170, 2020 Figure 3. Intravitreal injection of PFD downregulates the expression of TGFβ2 and VEGF. (A) Western blotting showed the expression of TGFβ2 and VEGF in the retinal pigment epithelium‑choroid‑sclera complex at day 7 after intravitreal injection of PFD or PBS. (B) Quantification graphs for TGFβ2 and VEGF. Data of the relative protein level normalized to that of GAPDH are presented as the mean ± SD. *P<0.05 vs. vehicle. TGFβ2, transforming growth factor β2; PFD, pirfenidone; VEGF, vascular endothelial growth factor. Figure 4. Intravitreal injection of PFD reduces the leakage area of CNV. (A) Fluorescent leakage surrounding the laser spots was relatively weak (score 1) in the PFD injection group compared with the control and vehicle injection groups (magnification, x100). (B) Extent of fundus fluorescein angi- ography leakage in the control, vehicle and PFD injection groups. **P<0.01 (n=24). CNV, choroidal neovascularization; PFD, pirfenidone. Figure 5. Intravitreal injection of PFD attenuates the formation of CNV. (A) Representative images of isolectin B4 (green) staining of the retinal pigment epithelium‑choroid‑sclera flat mounts obtained from the control, vehicle and PFD injection groups. Scale bar, 200 µm. (B) Quantitative measurement of the CNV area. **P<0.01 vs. vehicle. PFD, pirfenidone; CNV, choroidal neovascularization. the normal and injured retina, and this expression was signifi- cantly increased on day 28. In the normal mouse retina, TGFβ2 was localized to the ganglion cell layer (GCL) and outer plexiform layer (OPL). After laser photocoagulation (days 7 and 28), TGFβ2 could also be observed in the inner plexiform layer (IPL). The green labels were more intense on day 28 than on day 7. PFD suppresses the expression of TGFβ2 and VEGF. The level of TGFβ2 protein in the RPE‑choroid complex was found to be significantly reduced in the PFD injection group, compared with that measured in the control and vehicle injec- tion groups. This was also observed for VEGF (Fig. 3A and B). This suggested that PFD may inhibit the formation of CNV by downregulating the expression levels of TGFβ2 and VEGF. PFD alleviates the leakage of CNV. notably, in the control and vehicle injection groups, the brightness and size of the spot were almost identical (Fig. 4A). Fluorescein angiography showed that the leakage area of CNV was diminished in the PFD injection BAO et al: PIRFENIDONE AMELIORATES CHOROIDAL NEOVASCULARIZATION 2167 Figure 6. Intravitreal injection of PFD has no effect on the mouse retina. H&E staining images of choroidal neovascularization. Retinal and choroidal structure in the normal, vehicle and PFD groups. Scale bar, 50 µm. RPE, retinal pigment epithelium; OS, outer segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; PFD, pirfenidone. Figure 7. Intravitreal injection of PFD does not cause apoptosis. TUNEL labeling of the retinas obtained from the control, vehicle and PFD groups. Scale bar, 50 µm. OS, outer segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; PFD, pirfenidone; CNV, choroidal neovascularization. group (Fig. 4A). Meanwhile, PFD decreased the number of spots with extensive leakage (score ≥2), whereas it increased the number of spots with limited leakage (score 0 or 1; Fig. 4B). PFD reduces the area of CNV. The areas of isolectin B4 staining, marked with the green fluorescent mass in the image, were notably smaller in the PFD injection group than those observed in the control and vehicle injection groups (Fig. 5A). The difference in the quantitative measurement of the area of CNV formation was also statistically significant (Fig. 5B). Combined with the hypofluorescent leakage of the mouse retina shown on FFA, it was demonstrated that an injection of 0.5% PFD into the vitreous body of mice after laser photoco- agulation could block the formation of CNV and prevent the development of new blood vessels. Toxicity of PFD on the mouse retina. To confirm the safety of systemic PFD application, the retina in the region without CNV injury was collected from the PFD group and the histological changes were compared with the tissue from normal animals. Similar to the normal mice, the layers of the neural retina in the region without CNV in the PFD group were closely organized, well‑defined, and the cells were neatly arranged; there were no obvious morphological abnormalities (Fig. 6). Cryosections obtained from the normal, vehicle and PFD groups on day 28 were used for the TUNEL assay to analyze the effect of treat- ment with PFD on cell death in the mouse retina. There was no obvious difference in the apoptosis rate of the PFD group compared with the vehicle group (Fig. 7). This confirmed that the systemic application of PFD was safe to use on retinal tissue. Discussion In the present study, laser photocoagulation was used to induce a CNV model in male C57BL/6J mice. The immunofluorescent analysis of retinal cryosections showed that the localization of TGFβ2 in the mouse retina changes from the GCL and OPL in the normal retina to the GCL, OPL and IPL in the injured retina. Regarding the effect of PFD on CNV, three dimensions were analyzed to demonstrate that PFD could inhibit the formation of CNV by downregulating the expression of VEGF. Finally, H&E staining and a TUNEL assay showed that the administration of PFD did not cause damage to the mouse retina. It is well established that numerous cytokines, such as VEGF, matrix metalloproteinases (MMPs), tissue inhibitor for MMP3 (TIMP3) and TGFβ, are involved in different stages of 2168 Molecular Medicine rePorTS 21: 2162-2170, 2020 CNV (32). Specifically, VEGF plays a key role as an inciting stimulus involved in the development of CNV; it triggers the growth of vascular endothelial cells, enhances microvascular permeability and promotes monocyte chemotaxis (3,13). In elderly individuals, the expression levels of MMPs are increased, and responsible for the degradation of the extracel- lular matrix (ECM) (33). Meanwhile, TIMP3 can inhibit the expression of these MMPs in order to remodel the ECM. As a result, the ratio of MMPs to TiMP3 is essential for ecM turn- over, and controls pathology in the Bruch's membrane (34,35). TGFβ is upregulated during the development of CNV, stimu- lates the secretion of VEGF, and exerts a strong effect on the process of collagen remodeling and scar contraction (36). In addition, TGF blockages could inhibit angiogenesis and the formation of tissue fibrosis (7,29). Based on the present results, treatment with the TGFβ2 inhibitor PFD hindered the forma- tion and development of CNV. In the posterior segment of the human eye, TGFβ isoforms are distributed heterogeneously. TGFβ2 is localized in the connective tissue of large choroidal vessels, outer segment of photoreceptors, microglia, smooth muscle cells and pericytes of superficial retinal blood vessels (37). Ogata et al (38) and Yamamoto et al (39) reported that TGF β2 at both mrna and protein levels were detected in the GCL of normal and photocoagulated retinas of rats. In the present study, it was observed that TGFβ2 was mainly expressed in the GCL prior to laser injury, while limited expression was detected in the OPL. During the formation and development of CNV, the total expression of TGFβ2 increased. Interestingly, on days 7 and 28, the immunolocalization of TGFβ2 was noted in the GCL, OPL and IPL. Moreover, the immunoreaction was stronger in the mouse retina on day 28 compared with day 7. This finding suggested that TGFβ2 could affect cnV from the early to late stages. As mentioned in the introduction, PFD exerts its phar- macokinetic effect by modulating the TNFα and TGFβ pathways, and inhibiting the differentiation of fibroblasts into myofibroblasts (15). There is a body of evidence related to the anti‑fibrotic effects of PFD in vitro and in vivo. Kim et al (40) found that non‑toxic concentrations of PFD exert significant anti‑fibrotic effects on orbital fibroblasts from patients with thyroid‑associated ophthalmopathy. Chowdhury et al (41) indicated that PFD decreased collagen synthesis, prevented myofibroblast formation and improved corneal wound healing. After trabeculectomy surgery, Zhong et al (42) used 0.5% PFD eye drops to improve postoperative bleb survival. Previously, investigations on human Tenon's fibroblasts demonstrated that PFD could inhibit cell proliferation and migration (43,44). Yang et al (45) revealed that PFD inhibited the TGFβ2-induced proliferation, migration and epithelial‑mesenchymal transi- tion of human lens epithelial cells by downregulating the TGFβ/SMAD signaling pathway. Using a proliferative vitreo- retinopathy model, Khanum et al (25) confirmed that PFD prevented fibrotic changes involved in proliferative vitreoreti- nopathy. collectively, the present and previous results indicate that PFD could be a potential treatment of wet AMD, providing an alternative to the current methods used in the clinical setting. Both the present study and a previous study (46) have demon- strated that the local application of PFD can offer protection to the eye. It is proposed that intravenous injection should be carried out to assess the clinical application of the drug. This study used the laser‑induced CNV model, which has been shown to be repeatable and stable (26). However, there are a number of limitations of the present study. Firstly, the timeline of CNV inhibition, as well as the effect of PFD when new blood vessels are not formed or after the formation of cnV remains uncertain. Secondly, only the anti‑neovascular func- tion of PFD was examined (assays were only performed on day 7 post‑induction). In future investigations, its anti‑fibrotic functions and effects on the relationship between TGFβ2 and VEGF will be observed. In addition, this study mainly focused on the mechanisms involved in the protective effects of PFD, which were observed after the induction of CNV. To conclude, the local administration of PFD reduced the formation of CNV by downregulating the expression of VEGF. This indicated that the use of a TGFβ inhibitor may be a promising therapy for wet AMD. Acknowledgements Not applicable. Funding This study was supported by Nantong Science and Technology Project (grant no. MS22015085). Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Authors' contributions YB, LH, XH, CG, YC, LW and SZ performed the experi- ments and analyzed the data; YB and YS designed the study and wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved. Ethics approval and consent to participate All experimental procedures were performed in accordance with the requirements of the Animal Welfare Committee of Nantong University [permit nos. SCXK(Su) 2014‑0001 and SYXK(Su)2017‑0046]. This study adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The research protocol for the use of animals was approved by the Center for Laboratory Animals of Nantong University. Patient consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. BAO et al: PIRFENIDONE AMELIORATES CHOROIDAL NEOVASCULARIZATION 2169 References 1. Gehrs KM, Anderson DH, Johnson LV and Hageman GS: Age‑related macular degeneration‑emerging pathogenetic and therapeutic concepts. Ann Med 38: 450‑471, 2006. 2. Ambati J and Fowler BJ: Mechanisms of age‑related macular degeneration. Neuron 75: 26‑39, 2012. 3. Campa C, Costagliola C, Incorvaia C, Sheridan c, Semeraro F, De Nadai K, Sebastiani a and Parmeggiani F: Inflammatory mediators and angiogenic factors in choroidal neovasculariza- tion: Pathogenetic interactions and therapeutic implications. Mediators Inflamm 2010, 2010. 4. Ambati J, Atkinson JP and Gelfand BD: Immunology of age‑related macular degeneration. Nat Rev Immunol 13: 438‑451, 2013. 5. van Lookeren Campagne M, LeCouter J, Yaspan BL and Ye W: Mechanisms of age‑related macular degeneration and therapeutic opportunities. J Pathol 232: 151‑164, 2014. 6. Recalde S, Zar ranz‑Ventura J, Fernández‑Robredo P, García-Gómez PJ, Salinas‑Alamán A, Borrás‑Cuesta F, dotor J and García-layana a: Transforming growth factor‑β inhibi- tion decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. Invest Ophthalmol Vis Sci 52: 7090‑7097, 2011. 7. Zar ranz‑Ventura J, Fernández‑Robredo P, recalde S, Salinas‑Alamán A, Borrás‑Cuesta F, dotor J and García-layana a: Transforming growth factor‑beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides. PLoS One 8: e65434, 2013. 8. Ding D, Li C, Zhao T, Li D, Yang L and Zhang B: LncRNA H19/miR‑29b‑3p/PGRN axis promoted epithelial‑mesenchymal transition of colorectal cancer cells by acting on Wnt signaling. Mol Cells 41: 423‑435, 2018. 9. Verrecchia F and Rédini F: Transforming growth factor‑β signaling plays a pivotal role in the interplay between osteosar- coma cells and their microenvironment. Front Oncol 8: 133, 2018. 10. Stewart AG, Thomas B and Koff J: TGF‑β: Master regulator of inflammation and fibrosis. Respirology 23: 1096‑1097, 2018. 11. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, et al: role of TGF‑beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 105: 17504‑17509, 2008. 12. Saika S: TGFbeta pathobiology in the eye. Lab Invest 86: 106‑115, 2006. 13. Bressler SB: Introduction: U